泽泻萜类化合物对ApoE基因敲除动脉粥样硬化小鼠肝脏基底膜HSPG的调节作用

目的：观察泽泻萜类化合物对ApoE基因敲除小鼠实验性动脉粥样硬化肝脏基底膜硫酸乙酰肝素蛋白多糖的调节作用。方法：将8周龄C57／BL小鼠12只设为正常对照组，8周龄ApoE基因缺陷小鼠36只随机分为3组：模型组、中药组、舒降之阳性对照组。正常对照组、模型组予0．9％生理盐水灌胃，给药组正常人每kg体重的10倍量灌胃90天后，全自动生化仪测定血清血脂含量，用免疫印记法测定各组肝脏基底膜硫酸乙酰肝素蛋白多糖的表达，用Quantity One 6．0软件进行光密度分析。结果：中药组、阳性对照药组与模型组比较，总胆固醇、低密度脂蛋白水平均明显降低。中药组、阳性对照药组肝脏基底膜HSPG表达与模型组比较明显上调，但与正常对照组比较则明显下调。结论：泽泻萜类化合物对apoE-基因敲除高脂饲料喂养所致动脉粥样硬化小鼠具有降低血清总胆固醇、低密度脂蛋白的作用，对该模型小鼠的肝脏基底膜HSPG表达有调节作用。     

硫酸普拉睾酮钠胶囊处方及工艺的研究

目的研究硫酸普拉睾酮钠胶囊的制备处方和工艺。方法采用湿法制粒的制备工艺。结果确定了硫酸普拉睾酮钠胶囊的处方及最佳工艺条件。结论硫酸普拉睾酮钠胶囊制备工艺稳定、可靠。     

五种防腐剂在50%硫酸镁溶液中的溶解及防腐效果

目的筛选50%硫酸镁溶液的防腐剂.方法比较五种防腐剂在50%硫酸镁溶液的溶解情况以及防腐效果.结果在抑菌浓度范围内,度灭芬在50%硫酸镁溶液中溶解完全,防腐效果佳,苯甲酸次之.结论度灭芬作为50%硫酸镁溶液的防腐剂,效果最好.     

经口与经直肠硫酸吗啡控释片治疗癌痛的对比观察

目的比较硫酸吗啡控释片口服和直肠给药对中、重度癌性疼痛的疗效和不良反应。方法中、重度癌痛患者86例随机分为A组（46例）和B组（40例）,分别口服或直肠应用硫酸吗啡控释片治疗癌性疼痛。结果A组和B组的疼痛缓解率（84.8%,39/46例对82.5%,33/40例）和不良反应发生率（34.8%,16/46例对45.0%,18/40例）的差异无统计学意义。结论经直肠应用硫酸吗啡控释片控制癌性疼痛与经口给药一样安全、有效。     

硫酸钡比浊法测定水中硫酸盐的不确定度评估

目的分析和评估硫酸钡比浊法测定水中硫酸盐含量的不确定度。方法依据测量不确定度评定与表示（JJF1059-1999），建立数学模型，得出测定硫酸盐的合成小确定度和扩展不确定度。结果水中硫酸盐的合成不确定度为0．33mg／L，扩展不确定度为0．7mg／L。结论通过对硫酸钡比浊法测定水样中硫酸盐含量不确定度的来源分析，找出影响测量结果的各种因素，计算不确定度分量及合成不确定度，有效掌握了测量结果的可信程度和准确性，保证检测工作和检测结果的质量。     

Simultaneous analysis of metabisulfite and sulfate by CE with indirect UV detection. Application to and validation for a pharmaceutical formulation

Metabisulfite is used as an antioxidant agent in a number of pharmaceutical formulations. In order to quantify simultaneously both metabisulfite and its oxidation product (sulfate), a capillary zone electrophoretic (CZE) method with indirect UV detection was developed. Best results were achieved with a background electrolyte (BGE) constituted of 15 mM pyromellitic acid, 15 mM tris-(hydroxymethyl)-aminomethane and 0.2 mM tetradecyltrimethylammonium bromide at pH 8.3 and an applied electrical field of 123 V/cm in a 32.5 cm fused silica capillary. Indirect UV detection was performed at a wavelength of 225 nm. In order to validate this method, an internal standard (IS), namely ammonium formate, was used. Moreover, due to the high chloride concentration in the pharmaceutical formulation, conductivity was adjusted by adding sodium chloride into standard solutions to prevent matrix effect. Linearity and accuracy were successfully tested in a concentration range of 33.3–250 μg/ml for sodium metabisulfite and of 50–375 μg/ml for sodium sulfate. Method precision was determined on six samples each day. Thereby, relative standard deviations (R.S.D.) of 6% and 12–13% were obtained for intra-day and inter-day precision, respectively. Considering the instability of metabisulfite and its use as an antioxidant agent and not as an active principle, the method was accepted and used for routine analyses.     

In vitro Heparan Sulfate Modulates the Immune Responses of Normal and Tumor-Bearing Mice

Tumor-bearing (TB) patients and TB animal models show a wide array of immunologic deficits. Heparan sulfate (HS) has been shown to both improve immune cell proliferative responses and to induce Th1 cytokine responses in normal animals. These HS effects, if harnessed, would be of great benefit to TB patients. The present study focused on replicating previous HS-induced Th1 and proliferative response results as well as extrapolating the beneficial immunomodulatory effects to an experimental model derived from TB animals of Lewis lung cell carcinoma. Lewis Lung Carcinoma (LLC)-TB and control mouse splenocytes were assessed for proliferation and cytokine response to concanavalin A (Con A) with 1 and 3 days' exposure to HS. Our results found HS treatment stimulated splenocyte proliferation to Con A in control mice splenocytes after 1 and 3 days of treatment, although HS proliferative effects were not seen in unfractionated TB cultures. Furthermore, cytokine studies revealed normal splenocytes treated with HS had increased levels of both Th1 and Th2 cytokines. Surprisingly, HS treated TB-splenocytes showed suppressed cytokine levels. Of particular interest was the decreased levels of the Th2 cytokine IL-4 in TB-derived samples. In conclusion, we found that HS did show immune-modulator properties in both normal and TB environments. Our studies reinforced the possibility that HS could one day be used as an immune-modulating therapeutic agent.     

硫酸镁在支气管哮喘治疗中的应用观察

目的：观察硫酸镁在支气管哮喘治疗中的应用效果。方法：将151例支气管哮喘的住院患者，分为两组：对照组和观察组。对照组采用常规方法治疗，予常规吸氧祛痰、静点抗生素、氨茶碱和糖皮质激素等措施；观察组在常规治疗的同时．加用25％硫酸镁进行治疗。结果：两组结果经统计学处理，发现5d内两组治疗缓解率比较，差异有统计学意义（P〈0．05），不良反应发生率比较，差异亦有统计学意义（P〈0．05），说明观察组治疗效果优于对照组，观察组不良反应发生率低于对照组。结论：在常规药物治疗支气管哮喘基础上加用硫酸镁，可大大缩短支气管哮喘的持续时间．有效地提高治疗效果。     

Clinical (Nonforensic) Application of Ethyl Glucuronide Measurement: Are We Ready?

Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are minor metabolites of ethanol. Multiple studies have documented that, depending upon the amount of alcohol consumed, they can be measured in biological fluids for hours to days after the parent compound can no longer be detected. Testing for the presence of EtG, in a manner analogous to urinary drug abuse screening, has largely been restricted to forensic and law enforcement situations. Despite a real need for an objective and possibly quantitative marker of ethanol exposure for use in conjunction with outpatient clinical trials and treatment programs, measurement of these metabolites has seen only limited clinical application. The barriers to more extensive clinical use of EtG/EtS testing, particularly misleading assay results that can occur as a consequence of inadvertent exposure to nonbeverage ethanol‐containing substances, are reviewed and put into perspective. Additional information needed to develop guidelines for optimal clinical utilization of EtG/EtS measurements is discussed.     

关节镜下微创技术治疗股骨头颈部骨囊肿

目的探讨微创技术治疗股骨头颈部骨囊肿的方法和疗效。方法2005年8月-2008年4;1收治股骨头颈部骨囊肿9例,其中男6例,女3例,平均年龄43岁。经股骨大粗隆向囊肿中心打入导针,沿导针用环钻钻至囊肿腔内,在关节镜监视下刮除囊肿组织,植入可注射硫酸钙,骨块填塞骨道口。结果术后随访8例,失访1例,平均随访时间26．7个月（6—40个月）。影像学显示植入的硫酸钙及骨块与囊肿周围愈合,无复发病例。Harris评分由术前的69分提高至术后的92分。结论关节镜下手术能彻底刮除骨囊肿内壁的纤维结缔组织,利于植入物的愈合,手术创伤小,术后恢复快,疗效满意。